13F Holdings
中文EN

PURE PURE BIOSCIENCE, INC.

Miscellaneous Chemical Products · OTC · SEC CIK 1006028 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.3%
TTM net income YoY-3.5%
TTM EPS YoY0.0%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—

Margins

Gross margin57.3%
Operating margin-90.0%
Net margin-107.3%
FCF margin—
EBITDA margin-89.8%

Returns

ROE—
ROA-220.6%
ROIC (approx.)—
Asset turnover2.06x

Leverage & solvency

Liabilities / assets636.4%
Debt / equity—
Current ratio0.27x
Interest coverage-5.12x

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-66.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-07-31FY20252025-07-31FY20242024-07-31FY20232023-07-31FY20222022-07-31
Income statement
Revenue$2.31M$2.20M$1.96M$1.87M$1.81M
Cost of revenue$992,000$899,000$811,000$906,000$853,000
Gross profit$1.33M$1.30M$1.15M$971,000$1.00M
R&D expense$332,000$316,000$302,000$297,000$319,000
SG&A expense$3.08M$3.26M$3.98M$4.30M$4.05M
Operating income-$2.08M-$2.27M-$3.19M-$3.94M-$3.72M
Interest expense$407,000$299,000$155,000$14,000$6,000
Income tax$0$0$0$0$1,650
Net income-$2.48M-$2.40M-$3.35M-$3.96M-$3.49M
EBITDA-$2.08M-$2.27M-$3.04M-$3.83M-$3.51M
EPS (basic)-0.02-0.02-0.03-0.04-0.04
EPS (diluted)-0.02-0.02-0.03-0.04-0.04
Weighted avg. shares (diluted)116.46M111.86M111.86M111.40M88.84M
Balance sheet
Cash & equivalents$569,000$334,000$349,000$1.09M$3.39M
Receivables$334,000$474,000$298,000$285,000$201,000
Inventory$193,000$141,000$56,000$88,000$179,000
Current assets$1.19M$1.05M$805,000$1.60M$3.86M
PP&E, net$8,000$11,000$13,000$221,000$620,000
Total assets$1.19M$1.06M$818,000$1.82M$4.48M
Current liabilities$4.37M$2.11M$733,000$532,000$575,000
Long-term debt$6.60M————
Total debt$6.60M————
Total liabilities$7.59M$6.17M$3.68M$1.55M$575,000
Shareholders' equity-$6.40M-$5.12M-$2.86M$272,000$3.91M
Net debt$6.03M————
Shares outstanding130.02M111.89M111.86M111.86M111.36M
Cash flow statement
Operating cash flow-$1.74M-$2.02M-$2.53M-$3.28M-$2.42M
Capital expenditure———$33,000$81,000
Free cash flow———-$3.31M-$2.50M
Investing cash flow———-$33,000-$81,000
Financing cash flow$1.97M$2.00M$1.78M$1.01M$3.50M
Depreciation & amortization$3,000$2,000$148,000$117,000$213,000
Stock-based compensation$197,000$147,000$214,000$324,000$567,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.